Endocrine Abstracts

Introduction: In transsexualism, cross-sex hormone treatment (CHT) both improves and impairs several surrogate cardiovascular risk markers in female to male (FtoM). Few randomized trials on CHT with long follow-up and control group are available, and present evidence is inconsistent. We here assess changes in metabolic and cardiovascular risk after 12 months CHT compared with biological sex in FtoM GID.Methods: Prospective observational study, including ...

Introduction: Familial non-medullary thyroid cancer(FNMTC) represents 3–9% of thyroid cancer cases. Although the susceptibility genes for syndromic FNMTC are known, most cases of FNMTC are nonsyndromic and the genetic causes are unknown.Patients and methods: We conducted a multicenter study to identify a candidate susceptibility gene for nonsyndromic FNTMC. We collected blood specimens, clinical and pathological data from 38 kindreds with FNMTC (32 ...

Objectives: To assess baseline differences on lipid profile in individuals with gender identity disorder (male to female, M2F and female to male, F2M) in relation to prior cross-sex hormone treatment (CHT) or not, and changes in the lipid profile after 24 months of treatment and follow-up in our unit.Methods: Transversal study by revision of medical records of 235 patients visited for first time in our service from 2006 to 2010. Clinical and analytical r...

Introduction: Previous studies indicate a high prevalence of HIV infection in the transgender population and associate it with sexual risk behavior, psychiatrical and socio-economic problems. Anyway, few data are available regarding other factors. We assessed the prevalence of HIV and other associated characteristics in a transgender population of Catalonia.Methods: Cross-sectional study including 234 transsexuals that started follow-up in a reference ce...

Introduction: Transsphenoidal surgery (TSS) is the procedure of choice in Cushing disease (CD), with immediate post-operative remission rates ranging between 59 and 94% and recurrence rates between 3 and 46%, both depending upon the definition criteria and the duration of the follow-up. Our aim was to assess the rate of remission, recurrence and persistence of the disease after the first treatment and to identify predictors of remission in the CD population of our center durin...